DMBT1 / GP340 Antibody (Antigen Affinity Purified)

Deleted in Malignant Brain Tumors 1 Protein Antibody (Antigen Affinity Purified)

DMBT1 / GP340 Antibody Product Information

• Immunogen: Recombinant human DMBT1 protein ( Catalog#11678-H08H )
• Antibody Type: Rabbit Polyclonal Antibody ( Antibody Purification Platform )
• Ig Type: Rabbit IgG
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: Produced in rabbits immunized with purified, human cell-derived, recombinant human DMBT1 ( rh DMBT1 ; Catalog#11678-H08H ; NP_004397.2 ; Met 1 - Ser 220 ). DMBT1 specific IgG was purified by human DMBT1 affinity chromatography

DMBT1 / GP340 Antibody Usage Guide

• Specificity: Human DMBT1 / GP340
• Western blot: This antibody can be used at 0.1 - 0.2 μg/mL with the appropriate secondary reagents to detect human DMBT1 in WB. Using a DAB detection system, the detection limit for human DMBT1 is approximately 8 ng/lane under non-reducing conditions and 4 ng/lane under reducing conditions
• Direct ELISA: This antibody can be used at 0.1 - 0.2 μg/mL with the appropriate secondary reagents to detect human DMBT1. The detection limit for human DMBT1 is approximately 0.00975 ng/well
• Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

DMBT1 / GP340 Antibody Background

Deleted in malignant brain tumors 1 protein, also known as glycoprotein 340, surfactant pulmonary-associated D-binding protein, DMBT1 and GP340, is a secreted protein which belongs to the DMBT1 family. DMBT1 contains 2 CUB domains, 14 SRCR domains and 1 ZP domain. It is highly expressed in alveolar and macrophage tissues. In some macrophages, expression is detected on the membrane, and in other macrophages, it is strongly expressed in the phagosome / phagolysosome compartments. Defects in DMBT1 are involved in the development of glioma (GLM). Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas , and ependymomas. 

DMBT1 may be considered as a candidate tumor suppressor for brain, lung, esophageal, gastric, and colorectal cancers. It may play roles in mucosal defense system, cellular immune defense and epithelial differentiation. DMBT1 may play a role as an opsonin receptor for SFTPD and SPAR in macrophage tissues throughout the body, including epithelial cells lining the gastrointestinal tract. It may be an important factor in fate decision and differentiation of transit-amplifying ductular (oval) cells within the hepatic lineage. DMBT1 may function as a binding protein in saliva for the regulation of taste sensation. It binds to HIV-1 envelope protein and has been shown to both inhibit and facilitate viral transmission.

References

1. Mollenhauer J. et al., 1997, Nat. Genet. 17: 32-9.
2. Holmskov U. et al., 1999, Proc. Natl. Acad. Sci. USA. 96:10794-9.
3. Prakobphol A. et al., 2000, J. Biol. Chem. 275: 39860-6.
4. Mollenhauer J. et al., 2001, Cancer Res. 61: 8880-6.
5. Wu Z. et al., 2006, AIDS Res. Hum. Retroviruses. 22: 508-15.
6. Rosenstiel P.et al., 2007, J. Immunol. 178: 8203-11.
7. Stoddard E. et al., 2007, J. Immunol. 179: 3126-32.
8. End C. et al., 2009, Eur. J. Immunol. 39: 833-42.